Fibrogammin P

PreclinicalSmall molecule

CChildren's Hospital of Orange County

Fibrogammin P is one of 34 small molecule programs targeting Clinical Trial. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical TrialCompleted

Clinical TrialPreclinical

Completed

Competition

Competitive Landscape

136 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Venclexta

AbbVie

Phase 3

2 3

Avelox

Bayer

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Opzelura

DDizal Pharmaceuticals

Phase 3

1 6

Potassium Iodide

MMeda Pharmaceuticals

Phase 3

1 7

Ablysinol

CSL Behring

Phase 3

1 8

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 9

Grafapex

MMedexus Pharma, Inc.

Phase 2

1 10

FOLFOXIRI

SSun Yat-sen University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Trial1 trial

Clinical Trial of Factor XIII (FXIII) Concentrate

Completed·—·N/A·NCT00640289·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fibrogammin P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fibrogammin P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fibrogammin P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Hospital of Orange County company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChildren's Hospital of Orange County

Fibrogammin P

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News